Community naloxone supply to prevent fatal overdose needs to consider patients using pharmaceutical opioids
Pharmaceutical Benefits Scheme (PBS) opioid prescriptions in Australia have increased from 2.4 million in 1992 to 7 million in 2007 to 15 million prescriptions in 2016.1 The corresponding rate of opioid mortality over this time almost doubled from 3.8 deaths per 100 000 Australians in 2007 to 6.7 in 2017,2 with fatal opioid overdoses increasing from 482 in 2002 per 100 000 Australians to 900 in 2018.3 Most of these deaths involved prescription opioids, and contrary to what many assume, only one‐third of prescription opioid‐related deaths involved intravenous drug use.4 Among deaths associated with common prescription opioids (including fentanyl, morphine, oxycodone, tramadol and codeine), 49% involved people with chronic pain.4
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Islam M, McRae I, Mazumdar S, et al. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing. Intern Med J 2016; 46: 955–963.
- 2. Chrzanowska A, Dobbins T, Degenhardt L, et al. Trends in drug‐induced deaths in Australia, 1997‐2017 (Drug Trends Bulletin Series). Sydney: National Drug and Alcohol Research Centre, UNSW Sydney, 2019. https://ndarc.med.unsw.edu.au/resource/trends-drug-induced-deaths-australia-1997-2017 (viewed Mar 2021).
- 3. Penington Institute. Australia’s annual overdose report 2020. Melbourne: Penington Institute, 2020. https://www.penington.org.au/wp-content/uploads/Australias-Annual-Overdose-Report-2020.pdf (viewed Mar 2021).
- 4. Roxburgh A, Hall WD, Gisev N, et al. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: comparison across opioids. Drug Alcohol Depend 2019; 205: 107533.
- 5. National Prescribing Service. Naloxone nasal spray (Nyxoid) for opioid overdose. 15 Jan 2020. https://www.nps.org.au/radar/articles/naloxone-nasal-spray-nyxoid-for-opioid-overdose (viewed Oct 2020).
- 6. McDonald R, Strang J. Are take‐home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016; 111: 1177–1187.
- 7. Penington Institute. Saving lives: Australian naloxone access model. Melbourne: Pennington Institute, 2018. https://www.penington.org.au/wp-content/uploads/2018/10/Saving-Lives-Australian-naloxone-access-model.pdf (viewed Oct 2020).
- 8. Lintzeris N, Nielsen S, Degenhardt L, et al. Estimating Centre for Disease Control and Prevention‐defined overdose risk in people prescribed opioids for chronic non‐cancer pain: implications for take‐home naloxone provision. Intern Med J 2019; 49: 1054–1055.
- 9. Lintzeris NW, Wilson H. Take‐home intranasal naloxone to prevent opioid overdose deaths. Med Today 2020; 21: 45–49.
- 10. Tse WC, Sanfilippo P, Lam T, et al. Community pharmacy naloxone supply, before and after rescheduling as an over‐the-counter drug: sales and prescriptions data, 2014–2018. Med J Aust 2020; 212: 314–320. https://www.mja.com.au/journal/2020/212/7/community-pharmacy-naloxone-supply-and-after-rescheduling-over-counter-drug
- 11. Lalic S, Gisev N, Bell JS, et al. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol 2018; 84: 1267–1278.
- 12. Prathivadi P, Barton C, Mazza D. Qualitative insights into the opioid prescribing practices of Australian GP. Fam Pract 2020; 37: 412–417.
- 13. Therapeutic Goods Administration. Consultation: prescription strong (Schedule 8) opioid use and misuse in Australia – options for a regulatory response. 23 May 2018. https://www.tga.gov.au/consultation/consultation-prescription-strong-schedule-8-opioid-use-and-misuse-australia-options-regulatory-response (viewed Oct 2020).
- 14. Nielsen S, Peacock A, Lintzeris N, et al. Knowledge of opioid overdose and attitudes to supply of take‐home naloxone among people with chronic noncancer pain prescribed opioids. Pain Med 2018; 19: 533–540.
- 15. Australian Government Services Australia. Pharmaceutical Benefits Schedule item reports. http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp (viewed Oct 2020).
No relevant disclosures.